Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Allam was serving recently as the CEO at Public Investment Fund
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The investment will enable the company to enter European markets as well as enhance margins in current markets
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The use of procalcitonin testing for sepsis management is highest in the US
Subscribe To Our Newsletter & Stay Updated